• About Us
  • Board of Advisors
  • Contact

MALARIA.com

A Malaria Information and Community Portal

  • Home
  • Malaria Overview
  • Malaria Research
  • News
  • Videos
  • Blogs
  • Malaria Q&A
  • Events
  • Jobs
Home / Malaria Q&A / Antimalarial Drug Therapeutic Life

Antimalarial Drug Therapeutic Life

December 5, 2011 By Malaria Q&A 1 Comment

QUESTION

Why do some antimalarial drugs have long therapeutic life while others have short therapeutic lives?

ANSWER

Different anti-malarial drugs target slightly different aspects of the malaria Plasmodium parasite, and so are made with different chemical structures.

The differences in therapeutic life across different malaria drugs has to do with the specific pharmacokinetic properties of the chemical compounds from which the drugs are made. Even drugs designed around the same principal chemical compound can persist for different amounts of time in the human body, depending on the other chemicals with which the active compound is bound. The length of time it takes for a chemical compound to halve in concentration, or for its pharmacological effect to reduce by half, in the human blood stream is known as its “half life.”

For example, the common anti-malarial drug chloroquine has a half life of about 10 days, and is based on a chemical compound called 4-aminoquinoline. However, another drug also based on 4-aminoquinoline, called amodioquine, has a half life of only 10 hours.

Proguanil (combined with atovaquone in the drug Malarone) is dihydrofolate reductase inhibitor with a half life of about 16 hours, while mefloquine (sold as Lariam), is made from quinoline methanol and has a half life ranging from 10-40 days. These differences in length of therapeutic action also affect the efficacy of the compounds against malaria at various stages in its progression, and can also be implicated in the propensity to resistance developing to the drug in the malaria parasite.

Filed Under: Malaria Q&A Tagged With: 4-aminoquinoline, amodioquine, anti-malarial drugs, Atovaquone, biological half life, Chloroquine, dihydrofolate reductase inhibitor, drug resistance, Lariam, Malaria Treatment, Malarone, Mefloquine, Plasmodium, proguanil, quinoline methanol

Comments

  1. Risa Alex says

    December 12, 2011 at 1:46 am

    It is evident that drugs with a pleiotropic (multiple) mode of action like mefloquine confer a longer useful therapeutic life (UTL) whereas drugs with single putative targets have a shorter UTL.

    Log in to Reply

Leave a Reply Cancel reply

You must be logged in to post a comment.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Stay Informed

WWARN Corner

About WWARN

The WorldWide Antimalarial Resistance Network (WWARN) generates innovative resources and reliable evidence to inform the malaria community on the factors affecting the efficacy of antimalarial medicines. Learn more…

  • Fighting Malaria Requires Protecting the Effectiveness of Antimalarial Medicines
  • Data Sharing at IDDO
  • Evidence to inform equitable dosing in very young and malnourished children

More WWARN Stories...

  • Home
  • Malaria Overview
  • Malaria Research
  • News
  • Videos
  • Blogs
  • Malaria Q&A
  • Events
  • Jobs
  • About Us
  • Board of Advisors
  • Contact

Copyright © 2025 Malaria.com · Log in